Skip to main content

Table 1 Demographic and baseline characteristics:

From: A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

Demographics

 

   Age Mean

66.5 ± 10.5

   Sex (male/female)

35/5

   White/Caucasian

36 (90%)

Cause of disease

 

   HBV/HCV/Ethanol

5 (12.5%)/15 (37.5%)/16 (40%)

ECOG - no (%)

 

   0

31 (77.5%)

   1

9 (22.5%)

BCLC stage - no (%)

 

   A

2 (5%)

   B

12 (30%)

   C

26 (65%)

Child - Pugh Score - no (%)

 

   A

38 (95%)

   B

2 (5%)

Prior Therapies - no (%)

 

   Prior therapy received

26 (65%)

Surgery

9 (23%)

Other type of therapy

25 (63%)

Biochemistry profile - Median ± SD (range)

 

   ALT (IU/L)

57.8 ± 31.1 (range 16 - 166)

   AST (IU/L)

81.2 ± 49.8 (range 23 - 229)

   Bilirubin (μmol/L)

17. 7 ± 12.8 (range 5.5 - 54.5)